RxDoctor Payments Data

Hannah Helm, PA

Medical · Bryan, TXNPI 1073056248

Payments from drug & device makers

$2,801in general payments, 2019–2025

Across 122 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$724
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$255
  • Johnson & Johnson$246
  • E.r. Squibb & Sons, L.L.C.$246
  • Takeda Pharmaceuticals U.S.A., Inc.$226
  • Gilead$212
  • plus $892 from 19 others

What the payments were for

  • Food & beverage$2,801100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,801 in reported general payments places this provider in the 70th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$30,030
Medicare patients
196
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase17$85,290
XifaxanRifaximin19$62,612
LinzessLinaclotide44$42,792
Mesalamine49$25,505
MovantikNaloxegol Oxalate33$22,607
TrulancePlecanatide21$20,034
Dexlansoprazole DrDexlansoprazole44$13,509
Colestipol Hcl59$6,319
Lansoprazole94$5,512
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates86$5,335
Pantoprazole Sodium366$4,731
Omeprazole161$3,475
Esomeprazole Magnesium100$3,403
Famotidine218$3,025
Budesonide DrBudesonide25$2,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$34$85,29017 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$255$82,64640 claims
AbbVieLinzess$724$42,79244 claims
Redhill Biopharma Inc.Movantik$30$22,60733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,490 medical providers in Texas.

Other medical in Bryan

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →